drugset / Trial / NCT01473251
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
RandomizedParallel-groupOpen-labelHealth-services research
Summary
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Timeline
- Start
- 2011-11
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | — |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | — |